Drug Search Results
More Filters [+]

Lanreotide

Alternative Names: lanreotide, somatuline, autogel
Latest Update: 2024-11-08
Latest Update Note: Clinical Trial Update

Product Description

Lanreotide autogel is a synthetic somatostatin analogue which has been FDA and EMA approved for unresectable, well to moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumor.  (Sourced from: https://pubmed.ncbi.nlm.nih.gov/30582380/)

Mechanisms of Action: SSTR Agonist,GHR Antagonist

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Morocco | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: Ipsen
Company Location: BOULOGNE BILLANCOURT CEDEX I0 92650
Company CEO: David Loew
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Lanreotide

Countries in Clinic: Australia, China, Italy, United States

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Neuroendocrine Tumors|Pancreatic Cancer

Phase 2: Carcinoid Tumor|Oncology Unspecified

Phase 1: Acromegaly|Type 2 Diabetes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

LOLA trial

P2

Unknown Status

Oncology Unspecified

2026-08-31

2024-513200-34-00

P2

Unknown Status

Unknown

2025-12-31

ACTRN12624000390583

P1

Recruiting

Acromegaly

2024-05-30

LOLA Trial

P2

Active, not recruiting

Oncology Unspecified

2023-12-17

Recent News Events